INT19429

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.08
First Reported 1991
Last Reported 2006
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 1.62
Pain Relevance 0.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MTRF1) cytoplasm (MTRF1)
MTRF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
spinal inflammation 2 98.42 Very High Very High Very High
Adalimumab 40 96.60 Very High Very High Very High
rheumatoid arthritis 69 90.72 High High
Infliximab 42 75.00 Quite High
methotrexate 23 66.24 Quite High
Analgesic 1 54.32 Quite High
cINOD 2 53.60 Quite High
corticosteroid 1 50.88 Quite High
Etanercept 8 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Vasculitis 1 99.30 Very High Very High Very High
Asthma 1 98.78 Very High Very High Very High
Low Back Pain 2 98.42 Very High Very High Very High
Systemic Lupus Erythematosus 19 97.94 Very High Very High Very High
Chronic Disease 1 97.34 Very High Very High Very High
Rheumatoid Arthritis 69 90.72 High High
Communicable Diseases 2 88.16 High High
Salivary Gland Disease 2 85.28 High High
Autoimmune Disease 3 76.60 Quite High
Infection 4 75.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In serum samples from 125 controls with 4 different chronic diseases (systemic lupus erythematosus, ankylosing spondylitis, bronchial asthma, and polyarteritis nodosa), levels of IgA-, IgA1-, and IgA2-RF were found to be increased in 7%, 7%, and 8%, respectively.
Positive_regulation (increased) of RF associated with asthma, spinal inflammation, vasculitis, systemic lupus erythematosus and chronic disease
1) Confidence 0.08 Published 1991 Journal Arthritis Rheum. Section Abstract Doc Link 2059231 Disease Relevance 0.91 Pain Relevance 0.26
Tests for IgM RF and anti-CCP autoantibodies were performed at baseline and after 6 and 12 months of adalimumab treatment.
Positive_regulation (Tests) of RF associated with adalimumab
2) Confidence 0.04 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0.44 Pain Relevance 0.25
The proportion of patients who were positive for rheumatoid factor (RF) was similar at baseline and at 78 weeks (87% and 80%, respectively).
Positive_regulation (positive) of RF
3) Confidence 0.03 Published 2004 Journal Arthritis Res Ther Section Abstract Doc Link PMC416448 Disease Relevance 0.28 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox